Effectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed

Jena, Germany (ots) - New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published [1]

Use of targeted intra-operative radiotherapy (TARGIT), as a single dose - with ZEISS INTRABEAM - directly after removal of a tumor, confirmed as non-inferior, when compared with external beam radiotherapy (EBRT). Within the accuracy of the study, the risk of a local tumor recurrence in the breast is similar and non-breast cancer death is reduced. The TARGIT-A randomized, multi-center phase 3 study involving 2298 patients with a median patient follow-up time of 8.6 years meets the highest scientific standards.

Globally more than 40,000 patients have already been treated, in over 350 breast cancer centers, with the TARGIT method. "Single dose intra-operative radiotherapy for early stage breast cancer can be a better alternative to conventional whole breast radiotherapy for most patients during primary tumor management " stated the principal investigator Professor Jayant Vaidya, Professor of Surgery and Oncology and Scientific Director at University College London when presenting the results of the study. "These excellent results provide real clinical justification for single intraoperative radiation in suitable patients with early breast cancer. It is now essential to develop the corresponding treatment guidelines as soon as possible", added Professor Jeffrey Tobias, Professor of Oncology at University College London and joint initiator of the TARGIT-A study.

Positive clinical study results validate TARGIT as an option in breast cancer treatment

The local, recurrence-free survival rate of women treated with single dose TARGIT is non-inferior when compared with EBRT. The mortality in the TARGIT arm was even lower because of fewer cardio-vascular deaths.

"We are delighted with the positive results, as the ZEISS INTRABEAM 600 now represents an outstanding treatment alternative for many patients. We are confident that the procedure can now find its way into everyday clinical practice" said Ludwin Monz, CEO of Carl Zeiss Meditec AG.

[1] https://www.bmj.com/content/370/bmj.m2836

TARGIT method underscored as an efficiency-oriented treatment

'This study reflects two decades of interdisciplinary clinical research by leading radiation oncologists, surgeons, physicists and health economists. The TARGIT-A trial has offered many breast cancer patients a treatment that is well tolerated, effective, convenient and highly cost efficient', summarized Professor William Small, Professor of Radio-oncology at Loyola University, Chicago and one of the world's leading radiation oncologists.

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world's leading medical technology companies and is included in the German MDAX and TecDAX stock indices. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The company offers complete solutions for the diagnosis and treatment of eye diseases - including implants and consumables. In microsurgery, the Company provides innovative visualization solutions. With approximately 3,230 employees worldwide, the company generated revenue totaling EUR1,459.3 million in fiscal year 2018/19 (ended 30 September).

The company is headquartered in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the US, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading companies in the optical and optoelectronic industries.

For more information please visit: www.zeiss.com/med (http://www.zeiss.de/med)

Contact:

Contacts for the press: Petra Rettenmaier Head of Marketing Communications Visualization Carl Zeiss Meditec AG Phone: +49 7364 204-232 Email: press.meditec@zeiss.com

Contact for investors Sebastian Frericks Director of Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220-116 Email: investors.meditec@zeiss.com http://www.zeiss.de/presse

Additional content: http://presseportal.de/pm/110480/4690239 OTS: Carl Zeiss Meditec AG ISIN: DE0005313704

Original-Content von: Carl Zeiss Meditec AG, übermittelt durch news aktuell